You are here

  • Home
  • Archive
  • Volume 80, Issue 1
  • EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Article metrics

Article menu
Recommendation
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: April 2020 to April 2025

AbstractFullPdf
Apr 2020915854512
May 202014291408918
Jun 202011081098577
Jul 2020622601318
Aug 2020539522257
Sep 2020695690281
Oct 2020524515268
Nov 2020450437203
Dec 2020750739336
Jan 2021837828406
Feb 2021636616320
Mar 2021752731337
Apr 2021591573299
May 2021586557272
Jun 2021588565279
Jul 2021487473178
Aug 2021470452206
Sep 2021593574234
Oct 2021552531295
Nov 2021580563237
Dec 2021574567201
Jan 2022514523221
Feb 2022414400149
Mar 2022656690288
Apr 2022558571271
May 2022563561222
Jun 2022477497249
Jul 2022398401140
Aug 2022397384141
Sep 2022444443144
Oct 2022490496171
Nov 2022479454174
Dec 2022370360163
Jan 2023417399157
Feb 2023459440295
Mar 2023546531188
Apr 2023419400176
May 2023468455183
Jun 2023520500200
Jul 2023532507122
Aug 2023409393135
Sep 2023511499243
Oct 2023560543187
Nov 2023565558175
Dec 2023414387199
Jan 2024413368227
Feb 2024461407259
Mar 2024604594324
Apr 2024569550337
May 2024645610276
Jun 2024545523320
Jul 2024498472243
Aug 2024477451240
Sep 2024523513248
Oct 2024548531298
Nov 2024584562275
Dec 2024587579270
Jan 2025421395178
Feb 2025432424157
Mar 2025367370133
Apr 2025359362125
Total338913299715437